{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T02:54:40Z","timestamp":1781319280266,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Intas Pharmaceutical Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s40261-020-00987-3","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T19:03:54Z","timestamp":1606244634000},"page":"29-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects"],"prefix":"10.1007","volume":"41","author":[{"given":"Inderjeet","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshul","family":"Attrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronak","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6164-0632","authenticated-orcid":false,"given":"Vinu","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"987_CR1","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1182\/blood.V120.21.4232.4232","volume":"120","author":"D Weycker","year":"2012","unstructured":"Weycker D, Barron R, Kartashov A, Legg JC, Lyman GH. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in inpatient and outpatient settings. Blood. 2012;120:4232\u20134232.","journal-title":"Blood"},{"key":"987_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2014.001492","author":"D Weycker","year":"2014","unstructured":"Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, et al. Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract. 2014. https:\/\/doi.org\/10.1200\/JOP.2014.001492.","journal-title":"J Oncol Pract"},{"key":"987_CR3","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187\u2013205.","journal-title":"J Clin Oncol."},{"key":"987_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.62.3488","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015. https:\/\/doi.org\/10.1200\/jco.2015.62.3488.","journal-title":"J Clin Oncol"},{"key":"987_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8823","author":"NM Kuderer","year":"2016","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2016. https:\/\/doi.org\/10.1200\/JCO.2006.08.8823.","journal-title":"J Clin Oncol"},{"key":"987_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-7073-2_8","author":"NM Kuderer","year":"2010","unstructured":"Kuderer NM. Meta-analysis of randomized controlled trials of granulocyte colony-stimulating factor prophylaxis in adult cancer patients receiving chemotherapy. Hematop Growth Factors Oncol. 2010. https:\/\/doi.org\/10.1007\/978-1-4419-7073-2_8.","journal-title":"Hematop Growth Factors Oncol"},{"key":"987_CR7","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24:2475\u201384.","journal-title":"Ann Oncol."},{"key":"987_CR8","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/03007995.2018.1519504","volume":"35","author":"D Weycker","year":"2019","unstructured":"Weycker D, Hanau A, Lonshteyn A, Bowers C, Garawin T, Bensink M, et al. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims. Curr Med Res Opin. 2019;35:725\u201330.","journal-title":"Curr Med Res Opin."},{"key":"987_CR9","unstructured":"Neulasta (Pegfilgrastim) Prescribing Information, Amgen Inc., USA. [Internet]. 2020. https:\/\/www.pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/neulasta\/neulasta_pi_hcp_english.pdf."},{"key":"987_CR10","unstructured":"Neupogen (Filgrastim) Prescribing Information, Amgen Inc., USA. [Internet]. 2018. https:\/\/www.pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/neupogen\/neupogen_pi_hcp_english.pdf."},{"key":"987_CR11","unstructured":"Neulasta (pegfilgrastim). Summary of Product Characteristics (SPC). Amgen Europe B.V [Internet]. 2018. https:\/\/www.medicines.org.uk\/emc\/product\/6770\/smpc."},{"key":"987_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1634\/theoncologist.2017-0348","volume":"23","author":"N Harbeck","year":"2018","unstructured":"Harbeck N, Gasc\u00f3n P, Krendyukov A, Hoebel N, Gattu S, Blackwell K. Safety profile of biosimilar filgrastim (Zarzio\/Zarxio): a combined analysis of phase III studies. Oncologist. 2018;23:403.","journal-title":"Oncologist"},{"key":"987_CR13","unstructured":"US Food and Drug Administration Guidance for Industry. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. [Internet]. 2016. https:\/\/www.fda.gov\/media\/88622\/download."},{"key":"987_CR14","unstructured":"US Food and Drug Administration Guidance for Industry. Scientific considerations in demonstrating biosimilarity to a reference product. [Internet]. 2015. https:\/\/www.fda.gov\/media\/82647\/download."},{"key":"987_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/cpdd.269","volume":"5","author":"K Desai","year":"2016","unstructured":"Desai K, Catalano T, Rai G, Misra P, Shah N. Confirmation of biosimilarity in a pharmacokinetic\/pharmacodynamic study in healthy volunteers for an analytically highly similar pegfilgrastim. Clin Pharmacol Drug Dev. 2016;5:354\u201363.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"987_CR16","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/S0301-472X(99)00112-5","volume":"27","author":"G Molineux","year":"1999","unstructured":"Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol. 1999;27:1724\u201334.","journal-title":"Exp Hematol."},{"key":"987_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00280-018-3620-x","volume":"82","author":"I Singh","year":"2018","unstructured":"Singh I, Patel A, Patel R, Jose V. Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects. Cancer Chemother Pharmacol. 2018;82:329\u201337.","journal-title":"Cancer Chemother Pharmacol."},{"key":"987_CR18","unstructured":"US Food and Drug Administration Guidance for Industry. Immunogenicity assessment for therapeutic protein products. [Internet]. 2014. https:\/\/www.fda.gov\/media\/85017\/download."},{"key":"987_CR19","unstructured":"US Food and Drug Administration Guidance for Industry. Bioavailability and bioequivalence studies submitted in NDAs or INDs-general considerations [Internet]. 2014. https:\/\/www.fda.gov\/media\/88254\/download."},{"key":"987_CR20","unstructured":"US Food and Drug Administration Draft Guidance for Industry. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA [Internet]. 2013. https:\/\/www.fda.gov\/media\/87219\/download."},{"key":"987_CR21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1177\/0091270006288731","volume":"46","author":"LK Roskos","year":"2006","unstructured":"Roskos LK, Lum P, Lockbaum P, Schwab G, Yang B-B. Pharmacokinetic\/pharmacodynamic modeling of Pegfilgrastim in healthy subjects. J Clin Pharmacol. 2006;46:747\u201357.","journal-title":"J Clin Pharmacol."},{"key":"987_CR22","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1111\/bcp.13731","volume":"84","author":"R Nakov","year":"2018","unstructured":"Nakov R, Gattu S, Wang J, Velinova M, Schaffar G, Skerjanec A. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects. Br J Clin Pharmacol. 2018;84:2790\u2013801.","journal-title":"Br J Clin Pharmacol."},{"key":"987_CR23","first-page":"6503","volume":"27","author":"CF Waller","year":"2016","unstructured":"Waller CF, Tiessen R, Lawrence T, Shaw A, Liu M, Sharma R, et al. A pharmacokinetics and pharmacodynamics equivalence trial of proposed pegfilgrastim biosimilar, MYL-1401H vs EU neulasta\u00ae and US neulasta\u00ae. Ann Oncol. 2016;27:6503.","journal-title":"Ann Oncol"},{"key":"987_CR24","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/bcp.14226","volume":"86","author":"A Bellon","year":"2020","unstructured":"Bellon A, Wang J, Skerjanec A, Velinova M, Dickerson D, Sabet A, et al. A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics. Br J Clin Pharmacol. 2020;86:1139\u201349.","journal-title":"Br J Clin Pharmacol."},{"key":"987_CR25","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.clinthera.2020.05.020","volume":"42","author":"J Lickliter","year":"2020","unstructured":"Lickliter J, Kanceva R, Vincent E, Schueler A, Harrison-Moench E, Yue CS, et al. Pharmacokinetics and pharmacodynamics of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim neulasta in healthy subjects: a randomized, double-blind trial. Clin Ther. 2020;42:1508\u201318.","journal-title":"Clin Ther."},{"key":"987_CR26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/jjco\/hyp038","volume":"39","author":"N Yamamoto","year":"2009","unstructured":"Yamamoto N, Sekine I, Nakagawa K, Takada M, Fukuoka M, Tanigawara Y, et al. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia. Jpn J Clin Oncol. 2009;39:425\u201330.","journal-title":"Jpn J Clin Oncol."},{"key":"987_CR27","doi-asserted-by":"crossref","unstructured":"Roth K, Lehnick D, Wessels H, H\u00f6fler J, Gastl B, Jankowsky R. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg\u00ae, a pegfilgrastim biosimilar in healthy subjects. Pharmacol Res Perspect. 2019;7. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6691757\/.","DOI":"10.1002\/prp2.503"},{"key":"987_CR28","unstructured":"Udenyca (CHS-1701. Clinical Pharmacology Review. BLA 761039. [Internet]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/761039Orig1s000ClinPharmR.pdf."},{"key":"987_CR29","doi-asserted-by":"crossref","unstructured":"Wessels H, Lehnick D, H\u00f6fler J, Jankowsky R, Chamberlain P, Roth K. Pharmacodynamics, safety, and immunogenicity of Pelmeg\u00ae, a pegfilgrastim biosimilar in healthy subjects. Pharmacol Res Perspect. 2019;7. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6691755\/.","DOI":"10.1002\/prp2.507"},{"key":"987_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01387-x","author":"S Moosavi","year":"2020","unstructured":"Moosavi S, Borema T, Ewesuedo R, Harris S, Levy J, May TB, et al. PF-06881894, a proposed biosimilar to pegfilgrastim, versus US-licensed and EU-approved pegfilgrastim reference products (Neulasta\u00ae): pharmacodynamics, pharmacokinetics, immunogenicity, and safety of single or multiple subcutaneous doses in healthy volunteers. Adv Ther. 2020. https:\/\/doi.org\/10.1007\/s12325-020-01387-x.","journal-title":"Adv Ther"},{"key":"987_CR31","doi-asserted-by":"crossref","unstructured":"Wynne C, Schwabe C, Vincent E, Schueler A, Ryding J, Ullmann M, et al. Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta\u00ae in healthy subjects: a randomized, double-blind trial. Pharmacol Res Perspect [Internet]. 2020;8. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7183238\/.","DOI":"10.1002\/prp2.578"},{"key":"987_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","volume":"89","author":"M Lambertini","year":"2014","unstructured":"Lambertini M, Mastro DL, Andrea B, Paolo P. The five \u201cWs\u201d for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol. 2014;89:112\u201328.","journal-title":"Crit Rev Oncol Hematol."},{"key":"987_CR33","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1136\/ard.61.9.849","volume":"61","author":"A Tsukadaira","year":"2002","unstructured":"Tsukadaira A, Okubo Y, Takashi S, Kobayashi H, Kubo K. Repeated arthralgia associated with granulocyte colony stimulating factor administration. Ann Rheum Dis. 2002;61:849\u201350.","journal-title":"Ann Rheum Dis."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00987-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00987-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00987-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T14:20:21Z","timestamp":1659104421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00987-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["987"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00987-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"5 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Intas Pharmaceuticals Limited (Biopharma Division), India.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Inderjeet Singh and Dr. Vinu Jose are employees of Intas Pharmaceutical Ltd., India. Dr. Anshul Attrey, Dr. Adarsh Garg, and Mr. Ronak Patel are employees of Lambda Therapeutic Research Ltd., India.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Committee approval"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Dr. Inderjeet Singh and Dr. Vinu Jose were involved in the conception, design, or planning of the study; Dr. Anshul Attrey was responsible for overall conduct of the PK\/PD study; Dr. Adarsh Garg was responsible for overall conduct of the immunogenicity study; and Mr. Ronak Patel was a biostatistician for both the studies. All of the authors contributed to the analysis and interpretation of data, as well as preparation, review, and approval of the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}